SCHEMBL5651409

SCHEMBL5651409

CCOC(=O)c1sc2c(ccc(=O)n2Cc2ccccc2Cl)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
KDM4E B2RXH2 3/20 0.44
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 2/20 0.41
GRM6 O15303 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 4/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651454 0.89 ALDH1A1 (0.54) ALDH1A1MAPTLMNAMAPK1TDP1
SCHEMBL5651499 0.87 MDM2 (0.51) ALDH1A1MAPTLMNACYP1A2CYP2C19
SCHEMBL5650191 0.84 ALDH1A1 (0.47) ALDH1A1MAPTLMNAGAACYP1A2
SCHEMBL5653004 0.82 ALDH1A1 (0.41) ALDH1A1MAPTLMNAGAAKDM4E
SCHEMBL5652104 0.82 ALDH1A1 (0.53) ALDH1A1MAPTLMNAGAACYP1A2
SCHEMBL5648783 0.81 LMNA (0.45) ALDH1A1MAPTLMNAGAAKDM4E
SCHEMBL5652931 0.81 ACACB (0.53) ALDH1A1MAPTLMNAGAAKDM4E
SCHEMBL5653013 0.80 GABRA1 (0.47) ALDH1A1MAPTLMNAKDM4EMAPK1
SCHEMBL5648462 0.80 MAPK8 (0.51) ALDH1A1MAPTLMNAKDM4EMAPK1
SCHEMBL5651283 0.80 MAPK8 (0.40) ALDH1A1MAPTLMNAGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ALDH1A1 1498/4885MAPT 3795/4885LMNA 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.